Neurocrine Biosciences is set to detail its neuropsychiatry pipeline and scientific advancements during the 2026 NEI Fall Congress, running from November 5 to November 8 in Colorado Springs.
Neurocrine announced participation in the 2026 NEI Fall Congress on Nov. 5-8 and a special industry-sponsored session. The release contains no financial figures, guidance, or regulatory action, so it is unlikely to materially change the stock price.
Neurocrine Biosciences will present its latest clinical developments and scientific research at the 2026 Neuroscience Education Institute Fall Congress in Colorado Springs. The company plans to host an industry-sponsored session to highlight its growing neuropsychiatry portfolio.
The company aims to spotlight its scientific journey and provide updates on its expanding neuropsychiatry pipeline through an industry-sponsored session.